Jaguar8 commented on a stock · Sep 25, 2024 20:31

NEWS

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio (NASDAQ: ENTX) and OPKO Health, Inc. (NASDAQ: OPK) have announced positive results from their collaborative research on an oral oxyntomodulin (OXM) peptide tablet for obesity and metabolic disorders. The study, combining OPKO's proprietary long-acting OXM analog with Entera's N-Tab™ technology, aims to develop the first oral dual agonist GLP-1/glucagon peptide for once-daily treatment.

Key findings from the in vivo proof-of-concept PK/PD studies in rodent and pig models include:

Significant systemic exposure following a single dose
Favorable PK profile and bioavailability
High plasma concentrations with prolonged systemic exposure in pigs
Statistically significant reduction in plasma glucose levels in rats
The companies plan to present these data at an upcoming clinical conference and move towards IND-enabling efforts for the program.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

3208 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8169

Followers

Following

93K

Visitors